PS Targeting is HUGE w/MRI images and Biomarkers to back it up
Louis Gerstner ties to Memorial Sloan Kettering etc has daughter Elizabeth Gerstner that last updated in a more public release in Nov 2018 and I noticed NO stopping of that GMB trial with Bavituximab and I imagine some Biomarkers being cross analyzed with Alzheimer's MRI patient images are worth BILLIONS
Note: GMB here is Glio ...not to be confused with single atom thick Graphene...where GBM Graphene Based Materials in production as well for PS Targeting etc
_________
I guess some don't know what some don't know and those that hide PS Targeting fortunes will think twice to what one thinks one can get away with
_________
Neuro Oncol. 2018 Nov;
20(Suppl 6): vi191.
Published online 2018 Nov 5. doi: 10.1093/neuonc/noy148.792
PMCID: PMC6216505
NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE
Ina Ly,1
Jonathan Cardona,2
Andrew Beers,2
Ken Chang,2
James Brown,2
David Reardon,3
Isabel Arrillaga-Romany,4
Jorg Dietrich,1
Deborah Forst,1
Eudocia Lee,3
Justin Jordan,5
Lakshmi Nayak,3
Patrick Wen,6
Tracy Batchelor,4
Jayashree Kalpathy-Cramer,7 and
Elizabeth Gerstner1
1Massachusetts General Hospital, Boston, MA, USA 2Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, USA
3Dana-Farber Cancer Institute, Boston, MA, USA 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
5Massachusetts General Hospital, Department of Neurology, Boston, MA, USA
6Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
7Athinoula A. Martinos Center for Biomedical Imaging,
Boston, MA, USA
Abstract
BACKGROUND Glioblastoma and tumor endothelial cells express phosphatidylserine, a highly immunosuppressive membrane phospholipid. Bavituximab a chimeric monoclonal antibody binds to 2-glycoprotein 1 (2-GP1) to form a complex of 2-GP1 with phosphatidylserine, resulting in immune activation against tumor cells and anti-angiogenic effects. Phase I/II trials in other solid cancers have demonstrated response rates up to 85% when bavituximab was given with cytotoxic chemotherapy. Pre-clinical data in glioblastoma models suggested synergistic effects of phosphatidylserine blockade, radiation, and temozolomide (TMZ). METHODS In this ongoing phase II trial (NCT03139916), adult patients with IDH-wild-type newly diagnosed glioblastoma receive 6 weeks of chemoradiation, followed by 6 cycles of adjuvant TMZ (C1-C6 aTMZ). Bavituximab (3 mg/kg) is given weekly, starting week 1 of chemoradiation, for 18 weeks with the option to continue if tolerated. Physiologic MRIs are performed pre-treatment, pre-C1, pre-C3, and pre-C5 aTMZ. Within the enhancing tumor region, we measured median tumor Ktrans (reflecting vascular permeability) and relative cerebral blood volume (rCBV). Median percent changes during treatment were compared to pre-treatment values. RESULTS To date, 25 of 36 anticipated patients have enrolled (10 with MGMT promoter methylation). All patients underwent pre-treatment scans. 13 have evaluable pre-C1 and 8 pre-C3 aTMZ scans. On the pre-C1 MRIs, enhancing volume decreased by 39% and median tumor Ktrans and rCBV did not change significantly. On the pre-C3 MRIs, enhancing volume decreased by 11% and Ktrans and rCBV decreased by 17% and 21%, respectively. Five patients experienced radiographic disease progression after a median of 2.6 months and 1 patient died 76 days after diagnosis due to disease progression. Bavituximab was generally well tolerated.
CONCLUSIONS: Combining bavituximab with radiation and temozolomide results in decreased enhancing tumor volume, permeability, and cerebral perfusion. Continued patient accrual and imaging marker evaluation are underway to investigate the correlation be